Subgroup analyses stratified by gender and age.

<div><p>Background</p><p>Sodium zirconium cyclosilicate (SZC, Lokelma) is a novel hyperkalemia therapy, but comprehensive real-world safety data are lacking. This study aimed to characterize SZC-associated adverse events (AEs) using post-marketing surveillance.</p><p...

Full description

Saved in:

Bibliographic Details
Main Author:	Yinrui Fang (22169878) (author)
Other Authors:	Zilun Wu (18696883) (author), Qian Wu (209382) (author), Gangyi Chen (381813) (author)
Published:	2025
Subjects:	Medicine Cell Biology Genetics Neuroscience Pharmacology Biotechnology Evolutionary Biology Immunology Developmental Biology Cancer Mental Health Infectious Diseases Virology world safety data sodium zirconium cyclosilicate g ., ileus four disproportionality algorithms associated adverse events 564 ae reports 2004 &# 8211 term risks remain novel hyperkalemia therapy identified safety signals cardiac adverse events previously unreported aes aes peaked early signals met previously recognized preferred term initial therapy early phase xlink "> ventricular fibrillation using post study highlights study aimed research design prospective studies inherent constraints general disorders findings suggest cardiac failure algorithm thresholds 2023 ).
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Subgroup analyses stratified by gender and age.

Similar Items